#ESMO23 | Dr. Yoshiaki Nakamura shared updated data from the GALAXY arm of the CIRCULATE-Japan trial, further showcasing the ability of the #Signatera™ molecular residual disease (MRD) test to help identify patients with resectable colorectal cancer (#CRC) who are at an increased risk of recurrence and predict who are most likely to benefit from adjuvant chemotherapy. Read more about the key takeaways listed below in our press release ➡️ https://ow.ly/1iJl50PZIf6 🧬 Circulating tumor DNA (#ctDNA) negative patients continued to show exceptional disease free survival regardless of adjuvant chemotherapy (ACT) treatment. 🧬 The presence of post-surgical ctDNA was the most significant prognostic factor for disease recurrence and was predictive of chemotherapy benefit. 🧬 Early ctDNA dynamics were predictive of recurrence. 📷 via Adham Jurdi, MD, medical director of oncology for Natera
